Advanced Oncotherapy
Holding(s) in Company
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
1. Identity of the issuer or the underlying issuer |
Advanced Oncotherapy plc |
||||
2 Reason for the notification (please tick the appropriate box or boxes): |
|||||
An acquisition or disposal of voting rights |
√
|
||||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
√
|
||||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|||||
An event changing the breakdown of voting rights : |
|||||
Other (please specify): |
CHANGE TO THE NUMBER OF VOTING RIGHTS IN ISSUE, FOLLOWING THE RECENT EXERCISE OF WARRANTS
|
√
|
|||
3. Full name of person(s) subject to the |
Aviva plc & its subsidiaries |
||||
4. Full name of shareholder(s) |
Registered Holder:
Available on Request 7,068*
BNY Norwich Union Nominees Limited 160,341*
Chase (GA Group) Nominees Limited 1,803,265*
State Street Nominees Limited 328,573*
*denotes direct interest
Chase (GA Group) Nominees Limited 545,418
Chase Nominees Limited 120,117 Vidacos Nominees Limited 307,254 |
||||
5. Date of the transaction and date on |
3 August 2016 |
||||
6. Date on which issuer notified: |
4 August 2016 |
||||
7. Threshold(s) that is/are crossed or |
4% to 3% Change at Direct Interest Level
|
||||
8. Notified details: |
|||||||||||
A: Voting rights attached to shares viii, ix |
|||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
|||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
|||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
|||||||
Ordinary Shares GBP 0.25 GB00BD6SX109 |
3,297,036* |
3,297,036* |
3,272,036 |
2,299,247 |
972,789 |
3.91% |
1.66% |
||||
* Includes right to recall loaned shares (1,085)
|
|||||||||||
B: Qualifying Financial Instruments |
|||||||||||
Resulting situation after the triggering transaction |
|||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
|||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||
Resulting situation after the triggering transaction |
||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
Nominal |
Delta |
|||||
Total (A+B+C) |
|
Number of voting rights |
Percentage of voting rights |
3,272,036 |
5.57% |
9. Chain of controlled undertakings through which the voting rights and/or the |
|
The voting rights are managed and controlled by Aviva Investors Global Services Limited and Friends Provident International Limited, with the following chain of controlled undertakings:-
Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)
Friends Provident International Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Life Holdings UK Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Friends Life FPG Limited (wholly owned subsidiary of Aviva Life Holdings UK Limited) · Friends Life FPL Limited (wholly owned subsidiary of Friends Life FPG Limited) · Friends Life Limited (wholly owned subsidiary of Friends Life FPL Limited) · Friends Life and Pensions Limited (wholly owned subsidiary of Friends Life Limited) · Friends Provident International Limited (wholly owned subsidiary of Friends Life and Pensions Limited)
|
|
Proxy Voting: |
|
10. Name of the proxy holder: |
See Section 4 |
11. Number of voting rights proxy holder will cease |
|
12. Date on which proxy holder will cease to hold |
|
Figures are based on a total number of voting rights of 58,780,361 as per the Company’s ‘Exercise of Warrants, Issue of Shares and Holdings in Company’ announcement of 27 July 2016. |
14. Contact name: |
James Clark, Aviva plc |
15. Contact telephone number: |
01603 683853 |